Company / Shareholders' Equity
Decoy Therapeutics Inc. Shareholders' Equity History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$38.7M
FY2022
5-year range
-$1.3M / $38.7M
FY2018-FY2022
Trend
+74.7%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has increased for 3 consecutive years, from -$1M in FY2019 to $39M in FY2022.
Based on SEC 10-K filings.
$39M in FY2022 with a 5-year CAGR of -15.9%.
Improved from $11M to $39M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -15.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- Decoy Therapeutics Inc.'s shareholders' equity has grown for 3 consecutive years.
- 5-year CAGR of -15.9%, indicating a declining trend.
- In FY2022, shareholders' equity increased 74.7% year-over-year.
- Peak shareholders' equity was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $38.7M | +74.7% |
| FY2021 | $22.2M | +109.4% |
| FY2020 | $10.6M | +932.4% |
| FY2019 | -$1.3M | -104.4% |
| FY2018 | $29.1M | -68.4% |
| FY2017 | $92.2M | +1510.0% |
| FY2016 | -$6.5M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026